"Couderc Dinh & Associés Advises Investors in EVerZom's €10M Fundraising for Regenerative Medicine Development"

"Couderc Dinh & Associés advised investors in a €10M fundraising for EVerZom, which was supported by various funds including Capital Grand Est and the EIC fund. EVerZom focuses on developing a proprietary bioproduction platform and first-in-class therapeutic candidates using exosomes from mesenchymal stem cells. This funding will enable EVerZom to advance its clinical and industrial strategy, including launching a clinical study for its lead drug candidate, EVerGelTM, aimed at treating complex perianal fistulas in Crohn's disease. The advisory team included Frédéric Bucher, Frédéric Pelé, and Anastasia Dedyukhina."

**Press Release Summary** Couderc Dinh & Associés advised investors in a €10 million fundraising round for EVerZom, with participation from Capital Grand Est, the European Innovation Council (EIC Fund), Sorbonne Venture, Paris Business Angels, and the Capital Cell platform. EVerZom is developing a proprietary bioproduction platform and first-in-class therapeutic candidates based on exosomes derived from mesenchymal stem cells. The company's strategy focuses on combining exosomes with biomaterials to enhance their therapeutic efficacy. This funding will enable EVerZom to implement its clinical and industrial strategy to advance its proprietary product portfolio in regenerative medicine. It will also facilitate the launch of the first clinical study for its flagship drug candidate, EVerGel™, aimed at treating complex perianal fistulas in Crohn's disease. The team from Couderc Dinh & Associés that advised the investors on this transaction included Frédéric Bucher (Partner), Frédéric Pelé (Counsel), and Anastasia Dedyukhina (Legal Advisor).

"Couderc Dinh & Associés Advises Investors in EVerZom's €10M Fundraising for Regenerative Medicine Development"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads